Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2017

01-09-2017 | Clinical Study

Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume

Authors: Andrea Di Cristofori, Barbara Zarino, Claudia Fanizzi, Giorgia Abete Fornara, Giulio Bertani, Paolo Rampini, Giorgio Carrabba, Manuela Caroli

Published in: Journal of Neuro-Oncology | Issue 2/2017

Login to get access

Abstract

High grade gliomas (HGG) are tumors with a rapidly progressive course and the standard of care consists of surgery and chemo-radiotherapy. Elderly patients with HGG usually have a worse prognosis due to their comorbidities and difficulties in accessing or completing adjuvant treatments. The purpose of our study was to assess the influence of pre-operative factors (MMSE, age, sex, KPS, tumor volume) on the post-operative access to chemo-radiotherapy in the elderly population. In addition, the influence of the access to adjuvant therapies on overall survival (OS) was assessed. We retrospectively reviewed our consecutive case series of 117 elderly patients (≥65 years) with HGG treated in our Institution. All the clinical records regarding age, sex, tumor location, MMSE, KPS, access to adjuvant treatments and OS were analyzed. 72 males and 45 females with a median age of 71 years were analyzed. Adjuvant therapies were considered; concomitant chemo-radiotherapy with standard radiotherapy or hypofractionated radiation regimen. 84 patients had access to adjuvant therapies. Access to therapies was associated with a median age of 71(range 66–80) years, a median MMSE of 26(range 5–30), and a median tumor volume of 24 cm3(range 1–140). The median OS was 13 months for patients who had access to adjuvant therapies and 5 months for patients who did not. In the elderly patients with HGG, the MMSE, age and tumor volume were predictive of post-surgery access to adjuvant treatments. OS was significantly longer in elderly patients with HGG who had access to post-surgery chemo-radiotherapy.
Literature
5.
go back to reference Gorlia T, Stupp R, Brandes AA et al (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48:1176–1184. doi:10.1016/j.ejca.2012.02.004 CrossRefPubMed Gorlia T, Stupp R, Brandes AA et al (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48:1176–1184. doi:10.​1016/​j.​ejca.​2012.​02.​004 CrossRefPubMed
6.
go back to reference Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29–38. doi:10.1016/S1470-2045(07)70384-4 CrossRefPubMed Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29–38. doi:10.​1016/​S1470-2045(07)70384-4 CrossRefPubMed
11.
go back to reference The PERNO Study Group, Franceschi E, Depenni R et al (2016) Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol 128:157–162. doi:10.1007/s11060-016-2093-1 CrossRef The PERNO Study Group, Franceschi E, Depenni R et al (2016) Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. J Neurooncol 128:157–162. doi:10.​1007/​s11060-016-2093-1 CrossRef
16.
go back to reference Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. doi:10.1016/S1470-2045(12)70265-6 CrossRefPubMed Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. doi:10.​1016/​S1470-2045(12)70265-6 CrossRefPubMed
19.
go back to reference Bunevicius A, Tamasauskas S, Deltuva V et al (2014) Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective. Acta Neurochir (Wien) 156:367–374. doi:10.1007/s00701-013-1930-7 CrossRef Bunevicius A, Tamasauskas S, Deltuva V et al (2014) Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective. Acta Neurochir (Wien) 156:367–374. doi:10.​1007/​s00701-013-1930-7 CrossRef
21.
go back to reference Habets EJJ, Dirven L, Wiggenraad RG, et al (2015) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncol. doi:10.1093/neuonc/nov186 PubMed Habets EJJ, Dirven L, Wiggenraad RG, et al (2015) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncol. doi:10.​1093/​neuonc/​nov186 PubMed
22.
go back to reference Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
25.
26.
go back to reference DI Cristofori A, Carrabba G, Lanfranchi G et al (2013) Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res 33:3383–3389PubMed DI Cristofori A, Carrabba G, Lanfranchi G et al (2013) Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res 33:3383–3389PubMed
32.
go back to reference Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.1016/S1470-2045(09)70025-7 CrossRefPubMed Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.​1016/​S1470-2045(09)70025-7 CrossRefPubMed
33.
36.
go back to reference Huang J, Samson P, Perkins SM et al (2016) Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol. doi:10.1007/s11060-016-2331-6 PubMedCentral Huang J, Samson P, Perkins SM et al (2016) Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol. doi:10.​1007/​s11060-016-2331-6 PubMedCentral
Metadata
Title
Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume
Authors
Andrea Di Cristofori
Barbara Zarino
Claudia Fanizzi
Giorgia Abete Fornara
Giulio Bertani
Paolo Rampini
Giorgio Carrabba
Manuela Caroli
Publication date
01-09-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2537-2

Other articles of this Issue 2/2017

Journal of Neuro-Oncology 2/2017 Go to the issue